Kwofie, Samuel K.
Bajic, Vladimir B.
KAUST DepartmentComputational Bioscience Research Center (CBRC)
Applied Mathematics and Computational Science Program
Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division
Online Publication Date2010-09-29
Print Publication Date2011-01-01
Permanent link to this recordhttp://hdl.handle.net/10754/325450
MetadataShow full item record
AbstractProstate cancer (PC) is one of the most commonly diagnosed cancers in men. PC is relatively difficult to diagnose due to a lack of clear early symptoms. Extensive research of PC has led to the availability of a large amount of data on PC. Several hundred genes are implicated in different stages of PC, which may help in developing diagnostic methods or even cures. In spite of this accumulated information, effective diagnostics and treatments remain evasive. We have developed Dragon Database of Genes associated with Prostate Cancer (DDPC) as an integrated knowledgebase of genes experimentally verified as implicated in PC. DDPC is distinctive from other databases in that (i) it provides pre-compiled biomedical text-mining information on PC, which otherwise require tedious computational analyses, (ii) it integrates data on molecular interactions, pathways, gene ontologies, gene regulation at molecular level, predicted transcription factor binding sites on promoters of PC implicated genes and transcription factors that correspond to these binding sites and (iii) it contains DrugBank data on drugs associated with PC. We believe this resource will serve as a source of useful information for research on PC. DDPC is freely accessible for academic and non-profit users via http://apps.sanbi.ac.za/ddpc/ and http://cbrc .kaust.edu.sa/ddpc/. The Author(s) 2010.
CitationMaqungo M, Kaur M, Kwofie SK, Radovanovic A, Schaefer U, et al. (2011) DDPC: Dragon Database of Genes associated with Prostate Cancer. Nucleic Acids Research 39: D980-D985. doi:10.1093/nar/gkq849.
PublisherOxford University Press (OUP)
JournalNucleic Acids Research
PubMed Central IDPMC3013759
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
- DDEC: Dragon database of genes implicated in esophageal cancer.
- Authors: Essack M, Radovanovic A, Schaefer U, Schmeier S, Seshadri SV, Christoffels A, Kaur M, Bajic VB
- Issue date: 2009 Jul 6
- Dragon exploratory system on hepatitis C virus (DESHCV).
- Authors: Kwofie SK, Radovanovic A, Sundararajan VS, Maqungo M, Christoffels A, Bajic VB
- Issue date: 2011 Jun
- Database for exploration of functional context of genes implicated in ovarian cancer.
- Authors: Kaur M, Radovanovic A, Essack M, Schaefer U, Maqungo M, Kibler T, Schmeier S, Christoffels A, Narasimhan K, Choolani M, Bajic VB
- Issue date: 2009 Jan
- dPORE-miRNA: polymorphic regulation of microRNA genes.
- Authors: Schmeier S, Schaefer U, MacPherson CR, Bajic VB
- Issue date: 2011 Feb 4
- HCVpro: hepatitis C virus protein interaction database.
- Authors: Kwofie SK, Schaefer U, Sundararajan VS, Bajic VB, Christoffels A
- Issue date: 2011 Dec
Showing items related by title, author, creator and subject.
Methylation biomarkers for prostate cancerBajic, Vladimir B.; Mansour, Hicham; Incitti, Roberto (2015-10-15) [Patent]Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.
Anti-Cancer Activity of White Button Mushroom (Agaricus bisporus) on Prostate CancerFeng Qian, Sarah; Shammugasamy, Balakrishnan; Valtchev, Peter; Dehghani, Fariba (2019-01-20) [Poster]Anti-Cancer Effects of White Button Mushrooms (Agaricus bisporus) on Prostate Cancer INTRODUCTION •Prostate cancer is the most diagnosed cancer in men in Australia. Approximately 16,700 men were diagnosed with prostate cancer in 2017 with 3500 mortality cases. •Prostate cancer occurrence and progression has been shown to be associated with diet and lifestyle.2, 3 •Mushroom consumption may reduce cancer risk as they contain many bioactive compounds such as polysaccharides that have the ability to indirectly modulate the immune system. •Additionally, mushrooms are also high in proteins, and proteolytically derived peptides have been shown to have different activities compared to parent proteins. However, it is unclear whether these could directly have anticancer activity. HYPOTHESIS •Hydrolysing white button mushroom proteins with enzymes could produce peptides with anti-cancer activity towards prostate cancer cells. I - PROTEIN HYDROLYSIS •Mushroom proteins were resistant to hydrolysis, possibly due to enzyme inhibitors. The most affected proteins were between 34-80 kDa. •Elastase appears to be the most effective enzyme. •Enzymes in acidic solution resulted in precipitation whilst those in basic solution led to undesirable oxidation due to the presence of phenolic compounds. II – ANTI-PROLIFERATIVE EFFECTS •Enzymatic digestion, especially trypsin (CC-50=17.5), resulted in significantly higher cytotoxicity to PC-3 cells compared to crude (CC-50=23.8) (p=0.004). III – CELL CYCLE ARREST •Trypsin-digested extract resulted in a significant increase (p=0.004) with cells accumulating in the G2/M phase. •Proliferating cells treated with crude did not result in a significant increase in cells arrest compared to control. IV – APOPTOSIS •Apoptosis or induced cell death is observed in both crude protein and trypsin treated peptides evident by increased DNA fragmentation. •Trypsin-digested extract contribute to observed apoptosis due to arrest at G2/M phase. CONCLUSION •Mushroom derived proteolytic peptides have increased toxicity towards in vitro prostate cancer PC-3 cells compared to crude extracts. •Trypsin derived peptides were most active with cell cycle arresting potential and inhibitory effect towards proliferating cancer cells. •Anticancer mechanisms of mushroom extract were identified as apoptosis induction with cell cycle block and accumulation of cells in G2/M phase. •Future work includes investigating methods of complete protein hydrolysis, active peptides identification, in vivo testing, clinical trial, and synergy testing with other bioactive compounds. Anti-Cancer Activity of White Button Mushroom (Agaricus bisporus) on Prostate Cancer
Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cellsMoritz, Tom; Venz, Simone; Junker, Heike; Kreuz, Sarah; Walther, Reinhard; Zimmermann, Uwe (Tumor Biology, Springer Nature, 2016-02-05) [Article]The tumour protein D52 isoform 1 (PC-1), a member of the tumour protein D52 (TPD52) protein family, is androgen-regulated and prostate-specific expressed. Previous studies confirmed that PC-1 contributes to malignant progression in prostate cancer with an important role in castration-resistant stage. In the present work, we identified its impact in mechanisms leading to neuroendocrine (NE) transdifferentiation. We established for long-term PC-1 overexpression an inducible expression system derived from the prostate carcinoma cell line LNCaP. We observed that PC-1 overexpression itself initiates characteristics of neuroendocrine cells, but the effect was much more pronounced in the presence of the cytokine interleukin-6 (IL-6). Moreover, to our knowledge, this is the first report that treatment with IL-6 leads to a significant upregulation of PC-1 in LNCaP cells. Other TPD52 isoforms were not affected. Proceeding from this result, we conclude that PC-1 overexpression enhances the IL-6-mediated differentiation of LNCaP cells into a NE-like phenotype, noticeable by morphological changes and increased expression of typical NE markers, like chromogranin A, synaptophysin or beta-3 tubulin. Immunofluorescent staining of IL-6-treated PC-1-overexpressing LNCaP cells indicates a considerable PC-1 accumulation at the end of the long-branched neuron-like cell processes, which are typically formed by NE cells. Additionally, the experimentally initiated NE transdifferentiation correlates with the androgen receptor status, which was upregulated additively. In summary, our data provide evidence for an involvement of PC-1 in NE transdifferentiation, frequently associated with castration resistance, which is a major therapeutic challenge in the treatment of advanced prostate cancer.